Physician
Wollenschlager, Cynthia
Wollenschlager, Cynthia was paid $1.51M by Medicaid between Nov 2020 and Dec 2024, across 39 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 34% of everything it billed.
33Billing provider infoWOLLENSCHLAGER, CYNTHIA
DOWNERS GROVE, IL 60515
DOWNERS GROVE, IL 60515
33aNPI1124086087assigned 05/02/2006
33bProvider typeInternal Medicine Physician
28Total paid$1.51M
24GClaims29,997
24DCodes billed39
24AFirst – last monthNov 2020 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Illinois
Rank by total paid#25 of 3,722
Median peer was paid$26K
This provider vs. median59×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,428 | $105K | |
| 2021 | 7,705 | $506K | |
| 2022 | 7,557 | $472K | |
| 2023 | 6,302 | $204K | |
| 2024incomplete | 7,005 | $225K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 34% | 1,489 | 1,245 | $511K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 8,684 | 6,993 | $367K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 3,491 | 3,030 | $164K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 7.5% | 1,261 | 1,079 | $113K |
| 87486 | 4.7% | 1,546 | 1,296 | $71K | |
| 87581 | 4.7% | 1,541 | 1,291 | $70K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.2% | 4,170 | 3,465 | $64K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.1% | 2,021 | 1,628 | $47K |
| 99000 | 1.0% | 682 | 593 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 1,182 | 806 | $15K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 75 | 58 | $11K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 137 | 112 | $10K |
27 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 58 | $10K |
| 0002A | <1% | 139 | $6K | |
| 0001A | <1% | 138 | $6K | |
| 0011A | <1% | 135 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 442 | $5K |
| 0012A | <1% | 117 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 162 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 96 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 89 | $2K |
| 81002 | <1% | 742 | $2K | |
| 96136 | <1% | 38 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 17 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16 | $734.76 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 17 | $664.87 |
| 80053 | Comprehensive metabolic panel | <1% | 59 | $594.68 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 302 | $449.93 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28 | $443.36 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25 | $429.80 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 53 | $288.82 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46 | $264.04 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 102 | $217.24 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 238 | $203.39 |
| 99072 | <1% | 50 | $175.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 139 | $12.90 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 277 | $11.43 |
| 91301 | <1% | 118 | $0.79 | |
| 91300 | <1% | 75 | $0.53 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.